kesimpta solution
novartis pharmaceuticals canada inc - ofatumumab - solution - 20mg - ofatumumab 20mg - immunomodulatory agents
kesimpta
novartis ireland ltd - ofatumumab - multiple sclerosis, relapsing-remitting - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.1).
kesimpta solution for injection 20 mg/0.4ml pfp 20 mg/0.4 ml
شركة مستودع الأدوية الأردني - the jordan drugstore co - ofatumumab 20 mg/0.4 ml - 20 mg/0.4 ml
bonspri solution for subcutaneous injection
novartis pharma stein - ofatumumab - solution for subcutaneous injection - 20mg/0,4ml
bonspri solution for subcutaneous injection
novartis pharma stein - ofatumumab - solution for subcutaneous injection - 20mg/0,4ml
kesimpta
novartis israel ltd - ofatumumab - solution for injection - ofatumumab 50 mg/ml - ofatumumab - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features
bonspri injection
novartis south africa (pty) ltd - injection - see ingredients - each pre-filled syringe contains ofatumumab 20,0 mg